"In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalizations (a secondary endpoint) was observed.

Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...

The effectiveness and safety of therapeutic interventions are traditionally evaluated with periodic, single time-point assessments. In patients with cardiovascular disease, this often requires ...

University at Buffalo researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin.